-
2023-510253-42-00
4
2026-01-28
Adult patients aged 18 and over with unicentric hyalino-vascular Castl
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2024-511084-28-00
11
2026-01-12
Hypertrophic Cardiomyopathie
-
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
-
2025-521144-38-00
4
2025-12-23
Primary Central Nervous System Lymphoma
-
2022-501557-36-00
4
2025-12-19
PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
-
2024-512503-39-00
6
2025-12-19
Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-516789-13-00
6
2025-12-15
Severe asthma
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-511003-42-00
4
2025-12-11
BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-521398-15-00
5
2025-12-04
Immune system diseases
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521391-58-00
4
2025-11-28
Asthma
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2024-519590-19-00
4
2025-11-25
PD-L1 positive advanced colorectal cancer
-
2024-519779-24-00
4
2025-11-25
VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2023-506843-40-00
5
2025-10-29
Mycobacterium xenopi pulmonary infection
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-519495-83-00
4
2025-10-28
Digestive system diseases
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig